Clare Fiala1, Vathany Kulasingam2,3, Eleftherios P Diamandis1,2,3. 1. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. 2. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. 3. Department of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Cancer cells release circulating tumor DNA (ctDNA) into the bloodstream, which can now be quantified and examined using novel high-throughput sequencing technologies. This has led to the emergence of the "liquid biopsy," which proposes to analyze this genetic material and extract information on a patient's cancer using a simple blood draw. CONTENT: ctDNA has been detected in many advanced cancers. It has also been proven to be a highly sensitive indicator of relapse and prognosis. Sequencing the genetic material has also led to the discovery of mutations targetable by existing therapies. Although ctDNA screening is more expensive, it is showing promise against circulating tumor cells and traditional cancer biomarkers. ctDNA has also been detected in other bodily fluids, including cerebrospinal fluid, urine, saliva, and stool. The utility of ctDNA for early cancer detection is being studied. However, a blood test for cancer faces heavy obstacles, such as extremely low ctDNA concentrations in early-stage disease and benign mutations caused by clonal hematopoiesis, causing both sensitivity and specificity concerns. Nonetheless, companies and academic laboratories are highly active in developing such a test. CONCLUSION: Currently, ctDNA is unlikely to perform at the high level of sensitivity and specificity required for early diagnosis and population screening. However, ctDNA in blood and other fluids has important clinical applications for cancer monitoring, prognosis, and selection of therapy that require further investigation.
BACKGROUND:Cancer cells release circulating tumor DNA (ctDNA) into the bloodstream, which can now be quantified and examined using novel high-throughput sequencing technologies. This has led to the emergence of the "liquid biopsy," which proposes to analyze this genetic material and extract information on a patient's cancer using a simple blood draw. CONTENT: ctDNA has been detected in many advanced cancers. It has also been proven to be a highly sensitive indicator of relapse and prognosis. Sequencing the genetic material has also led to the discovery of mutations targetable by existing therapies. Although ctDNA screening is more expensive, it is showing promise against circulating tumor cells and traditional cancer biomarkers. ctDNA has also been detected in other bodily fluids, including cerebrospinal fluid, urine, saliva, and stool. The utility of ctDNA for early cancer detection is being studied. However, a blood test for cancer faces heavy obstacles, such as extremely low ctDNA concentrations in early-stage disease and benign mutations caused by clonal hematopoiesis, causing both sensitivity and specificity concerns. Nonetheless, companies and academic laboratories are highly active in developing such a test. CONCLUSION: Currently, ctDNA is unlikely to perform at the high level of sensitivity and specificity required for early diagnosis and population screening. However, ctDNA in blood and other fluids has important clinical applications for cancer monitoring, prognosis, and selection of therapy that require further investigation.
Authors: Jane W Liang; Gregory E Idos; Christine Hong; Stephen B Gruber; Giovanni Parmigiani; Danielle Braun Journal: Genet Epidemiol Date: 2022-05-18 Impact factor: 2.344
Authors: Jason Chibuk; Andi Flory; Kristina M Kruglyak; Nicole Leibman; Alexis Nahama; Nilesh Dharajiya; Dirk van den Boom; Taylor J Jensen; Jeffrey S Friedman; M Richard Shen; Francisco Clemente-Vicario; Ilya Chorny; John A Tynan; Katherine M Lytle; Lauren E Holtvoigt; Muhammed Murtaza; Luis A Diaz; Dana W Y Tsui; Daniel S Grosu Journal: Front Vet Sci Date: 2021-03-23
Authors: Christopher P Pacia; Jinyun Yuan; Yimei Yue; Lu Xu; Arash Nazeri; Rupen Desai; H Michael Gach; Xiaowei Wang; Michael R Talcott; Aadel A Chaudhuri; Gavin P Dunn; Eric C Leuthardt; Hong Chen Journal: Theranostics Date: 2022-01-01 Impact factor: 11.600